ACM
FLXN

Advent Capital Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Advent Capital Management’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10,000
Closed -$224K – 325
2018
Q1 		$224K Sell
10,000
-174,267
-95% -$4.25M ﹤0.01% 232
2017
Q4 		$4.61M Buy
184,267
+169,267
+1,128% +$4.14M 0.09% 142
2017
Q3 		$363K Buy
+15,000
New +$353K 0.01% 211

Other funds holding FLXN

MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Advent Capital Management's FLXN Position: Q2 2018 in Review

Advent Capital Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q2 2018, closing a stake of 10,000 shares — an estimated $224K sold.

Advent Capital Management first reported a position in FLXN in Q3 2017 and held it in 3 quarters. The position peaked at $4.61M in Q4 2017. 130 funds tracked by Wall St. Rank hold FLXN as of Q2 2018.

  • Advent Capital Management reported no remaining Flexion Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • Advent Capital Management sold 10,000 Flexion Therapeutics, Inc. shares in Q2 2018, an estimated $224K.
  • Advent Capital Management first reported a position in Flexion Therapeutics, Inc. in Q3 2017 and held it in 3 quarters.
  • Advent Capital Management's Flexion Therapeutics, Inc. position peaked at $4.61M in Q4 2017.
  • 130 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q2 2018.

Based on Advent Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.